Caxton Associates LLP Makes New Investment in Zoetis Inc. $ZTS

Caxton Associates LLP acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the first quarter, Holdings Channel.com reports. The firm acquired 5,647 shares of the company’s stock, valued at approximately $930,000.

A number of other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after acquiring an additional 189,287 shares during the period. Polen Capital Management LLC raised its position in Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Northern Trust Corp raised its position in Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares during the period. Goldman Sachs Group Inc. raised its position in Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after acquiring an additional 109,791 shares during the period. Finally, Brown Advisory Inc. raised its position in Zoetis by 7.6% during the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after acquiring an additional 312,746 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 0.2%

Shares of ZTS stock opened at $149.45 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market cap of $66.24 billion, a PE ratio of 25.72, a price-to-earnings-growth ratio of 2.40 and a beta of 0.89. The company has a 50-day moving average of $152.70 and a two-hundred day moving average of $157.56. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the firm posted $1.56 earnings per share. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ZTS shares. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday. Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.